ATLANTA, Nov. 9, 2005 (PRIMEZONE) -- OTC Stock Review announces that it has initiated coverage of Sunwin International Neutraceuticals Inc. (OTCBB:SUWN). Trading at 8 times fiscal '05 earnings, Sunwin International Neutraceuticals, Inc. poses a tremendous opportunity for U.S. investors to participate in the growth of the Chinese economy. One of 2,000 state-level companies authorized as the most important innovative high-tech pioneer businesses by the Chinese Central Government in March 2005, Sunwin's scientists announced the development of a new series of veterinary disinfectants against the Bird Flu Virus. Based on Chinese herbal technology that Sunwin owns, the disinfectant kills any kind of Bird Flu Virus, meets national sanitary standards, and does not cause pollution to the environment.
Sunwin International Neutraceuticals targets their line of neutraceutical products at 3 separate markets.
-- $5.5 million of SUWN's fiscal '05 revenue came from Stevioside, a
100% natural sweetener extracted from the leaves of the Stevia
rebaudiana plant.
-- $3.3 million of SUWN's fiscal '05 revenue came from their
veterinary medicine division.
-- $3 million of fiscal '05 revenues came from traditional Chinese
medicine formula extracts, sold on a wholesale basis to domestic
traditional Chinese medicine manufacturers and large animal
pharmaceutical companies.
The complete is available at http://www.otcstockreview.com/suwn.htm.
OTC Stock Review provides a comprehensive review of financial market coverage, specifically the microcap market, by newsletters, mutual funds, brokerage firm, and independent research firms. OTC Stock Review defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Members receive regular emails of stock opinions and market coverage, including both global and domestic. Please visit http://www.otcstockreview.com.
NOTE: The purpose of this release is to introduce the reader to OTCStockReview.com and Sunwin International Neutraceuticals Inc. OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Information and opinions presented in this release are solely for informative purposes and not intended, nor should they be construed as, investment advice. This document contains information obtained from public sources about Sunwin International Neutraceuticals Inc., but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of Sunwin International Neutraceuticals Inc. as profiled. OTC Stock Review has been compensated $10,000.00 to perform investor relations services for Sunwin International Neutraceuticals Inc. Officers, directors, and employees of OTC Stock Review, may hold a long or short equity position of a profiled Company and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled companies. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm